Tranilast alleviates skin inflammation and fibrosis in rosacea-like mice induced by long-term exposure to LL-37.

Autor: Jin H; Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100000, China; Department of Dermatology, North China University of Science and Technology Affiliated Hospital, Tangshan, 063000, China., Wu Y; Clinical Medical College, North China University of Science and Technology, Tangshan, 063210, China., Zhang C; Clinical Medical College, North China University of Science and Technology, Tangshan, 063210, China., Zheng R; Clinical Medical College, North China University of Science and Technology, Tangshan, 063210, China., Xu H; Health Science Center, North China University of Science and Technology, Tangshan, 063210, China., Yang J; Department of Dermatology, North China University of Science and Technology Affiliated Hospital, Tangshan, 063000, China. Electronic address: yjj1971321@163.com., Li L; Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100000, China. Electronic address: zoonli@sina.com.
Jazyk: angličtina
Zdroj: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2024 Dec 10; Vol. 737, pp. 150523. Date of Electronic Publication: 2024 Aug 08.
DOI: 10.1016/j.bbrc.2024.150523
Abstrakt: Rosacea, a prevalent chronic facial inflammatory condition, afflicts millions worldwide. Its multifaceted pathogenesis poses challenges for effective treatment. Tranilast (TR), an analog of a tryptophan metabolite, has demonstrated anti-inflammatory and anti-fibrotic properties across various diseases. Yet, its potential in rosacea treatment remains understudied. Here, we induced rosacea-like symptoms in mice via prolonged LL-37 injections and administered TR intervention. Our findings reveal that TR mitigated skin lesions, reduced skin thickness, and suppressed inflammatory cell infiltration within the dermis of LL-37 mice. Notably, TR downregulated the expression of rosacea-associated inflammatory cytokines (TNF-α, IL-6, IL-1β, and IL-18) and the antimicrobial peptide CAMP, while also inhibiting NLRP3 inflammasome activation and the TLR4 signaling pathway. Furthermore, TR attenuated LL-37-induced fibrosis and hindered the transforming growth factor-β1 (TGF-β1)/Smad2/3 pathway. In summary, our study underscores TR's therapeutic potential in rosacea by mitigating both skin inflammation and fibrosis, thereby offering a promising treatment avenue for this condition.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: